Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Denali Therapeutics Inc. (DNLI) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/11/2021 GN Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)
02/12/2021 GN Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)
02/05/2021 GN Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™
01/11/2021 GN Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors
01/08/2021 GN Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration
10/15/2020 GN Denali Therapeutics to Highlight Progress Across Broad Biotherapeutics Portfolio for Neurodegeneration Enabled by Its Blood-Brain Barrier (BBB) TV Platform at Virtual R&D Day Today
10/07/2020 GN Denali Therapeutics Announces Closing of Collaboration and Share Purchase Agreements with Biogen
08/07/2020 GN Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
08/06/2020 GN Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson's Patients
08/06/2020 GN Biogen and Denali to Collaborate on LRRK2 Program for Parkinson's Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
05/27/2020 GN Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
05/07/2020 GN Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
04/02/2020 GN Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic
02/27/2020 GN Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
01/31/2020 GN Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
01/28/2020 GN Denali Therapeutics Announces Pricing of Public Offering of Common Stock
01/27/2020 GN Denali Therapeutics Announces Proposed Offering of Common Stock
01/14/2020 GN Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson's Disease
11/06/2019 GN Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights
09/04/2019 GN Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson's Disease and Launch of Its Engage Parkinson's Website
08/06/2019 GN Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights
06/11/2019 GN Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs
02/15/2019 GN Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer's Disease
01/08/2019 GN Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS
12/10/2018 GN Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson's Disease
11/19/2018 GN Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi
11/01/2018 GN Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors for the Treatment of Neurological and Inflammatory Diseases
10/03/2018 GN CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials
08/09/2018 GN Denali Therapeutics Reports Second Quarter 2018 Financial Results
08/07/2018 GN Denali Therapeutics Appoints Dana Andersen, Ph.D., as Chief Technical and Manufacturing Officer
08/01/2018 GN Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program for Parkinson's Disease
05/30/2018 GN Denali Therapeutics Announces Early Exercise of Its Option to Acquire F-star Gamma
05/11/2018 GN Denali Therapeutics Reports First Quarter 2018 Financial Results
03/19/2018 GN Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy